Business Wire

CGTN

10.2.2021 19:16:04 CET | Business Wire | Press release

Share
CGTN: China Eyes Good Start to 14th Five-Year Plan Period Ahead of Spring Festival

A New Year is a new beginning. With this year's Spring Festival, or the Chinese Lunar New Year, just around the corner, China is also well prepared for the beginning of the 14th Five-Year Plan (FYP) period (2021-2025) and the centenary of the Communist Party of China (CPC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210210005816/en/

Ahead of the Spring Festival, Chinese President Xi Jinping extended Spring Festival greetings to all Chinese Wednesday at a reception in Beijing and called for a good start in boosting the country's development during the 14th FYP period so as to celebrate the Party's centenary with outstanding achievements.

Ready for a new journey in the 14th FYP period

Facts have once again proven that the system of socialism with Chinese characteristics has incomparable vitality and creativity, Xi said.

As long as the entire Party and the Chinese people of all ethnic groups rally closely around the CPC Central Committee, there is no difficulty that cannot be overcome, he said.

The year 2021 is crucial to China as the nation is set to achieve its first centenary goal within the set time frame – to complete the building of a moderately prosperous society in all respects – and begin the work towards the second goal, to fully build a modern socialist country.

Stressing the goal of promoting high-quality development, President Xi highlighted the importance of the country's new stage of development, the implementation of this new vision of development, and the construction of a new pattern of development in 2021.

To meet the people's ever-growing needs for a better life, efforts are needed in deepening supply-side structural reform while taking reform and innovation as the fundamental driving force, the Chinese president said.

Consolidating and expanding achievements in epidemic containment and economic and social development are necessary, he added.

Great achievements in 2020 as solid foundation

President Xi also looked back on the past year which he described as "extraordinary" in his New Year speech.

Xi hailed what has achieved in COVID-19 prevention, poverty alleviation, flood prevention, rescue and relief work, and reform and opening-up, and highlighted the country's progress in technology, economy and the Belt and Road construction.

China is one of the most resilient economies amid the ravaging pandemic and global economic slump. The country was among the first to have put the virus under control, to have resumed work and production and to have realized economic stability and recovery, which not only made it the first major economy in the world to register positive growth in 2020 but also brought confidence and hope to others in the world.

On November 23, as southwest China's Guizhou Province cleared all the names on its poverty list, China announced the eradication of absolute poverty and regional poverty.

At a symposium on securing a decisive victory in poverty alleviation in March, President Xi said lifting all rural residents living below the poverty line out of poverty by 2020 is a solemn promise made by the CPC Central Committee and it must be fulfilled on time.

Original article: here .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye